Table 1.

Mortality outcomes stratified by sex and HDL-C in the CANHEART and the Copenhagen Heart Studies

Observational cohort studies	N	Age (years)	Sex	Mean HDL-C (mg/dl)	Outcomes stratified by sex and high HDL-C	Hazard risk (confidence intervals)
Cardiovascular Health in Ambulatory Care Research Team (CANHEART)	631,762	57.2	55.4% women	55.2	Women: HDL-C > 71–80 mg/dl (reference 51–60 mg/dl)
					Cardiovascular mortality	0.97 (0.823–1.144)
					Cancer mortality	1.07 (0.937–1.209)
					Other mortality	0.98 (0.854–1.123)
					Women with HDL-C > 90 mg/dl	1.32 (1.01–1.71)
					Men: HDL-C > 90 mg/dl (reference 41–50 mg/dl)
					Cardiovascular mortality	1.39 (0.978–1.977)
					Cancer mortality	1.29 (0.952–1.760)
					Other mortality	1.72 (1.103–2.682)
Copenhagen City Heart Study and the Copenhagen General Population Study	116,508	57.5	55% women	59.5	Women: reference group HDL-C 77–96 mg/dl
					HDL-C 116–134 mg/dl: all-cause mortality	1.10 (0.83–1.46)
					HDL-C ≥ 135 mg/dl: all-cause mortality	1.68 (1.09–2.58)
					Cardiovascular mortality	2.89 (1.33–6.24)
					Cancer mortality	1.33 (0.56–3.19)
					Other mortality	1.51 (0.66–3.46)
					Men: reference group HDL-C 58–76 mg/dl
					HDL-C 97–115 mg/dl: all-cause mortality	1.36 (1.09–1.70)
					HDL-C ≥ 116 mg/dl: all-cause mortality	2.06 (1.44–2.95)
					Cardiovascular mortality	2.53 (1.24–5.18)
					Cancer mortality	1.76 (0.88–3.53)
					Other mortality	1.90 (0.95–3.82)